[{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breath Therapeutics, a Zambon Company, Initiates BOSTON-3 and BOSTON-4, Two Additional Clinical Studies for the Treatment of Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A new FDA Fast Track designation for Zambon","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson\u2019s Disease Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Switzerland","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Swi.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb\u00ae in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Ab-Biotics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19. A Probiotic Formula Reduces Symptom Duration and Viral Load, Increases Antibodies, and Improves Remission Rate Among Patients With Mild Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KABP022","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zambon Group SpA \/ Zambon","highestDevelopmentStatusID":"1","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase 3 PROMIS-I Study of CMS I-neb\u00ae in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Pari","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Cyclosporine A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Pari","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Zambon Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Zambon Group SpA \/ Zambon Group Spa","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Carbidopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."}]

Find Clinical Drug Pipeline Developments & Deals by Zambon Group SpA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Through the licensing agreement, Zambon will commercialize IPX203, an oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson’s disease.

                          Product Name : IPX203

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 27, 2024

                          Lead Product(s) : Carbidopa,Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Amneal Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Liposomal Cyclosporine A

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Pari

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults foll...

                          Product Name : L-CsA

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 01, 2023

                          Lead Product(s) : Liposomal Cyclosporine A

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Pari

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.

                          Product Name : Xadago

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 15, 2023

                          Lead Product(s) : Safinamide Mesylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Newron Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.

                          Product Name : Promixin

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 12, 2022

                          Lead Product(s) : Colistimethate Sodium

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic,...

                          Product Name : Promixin

                          Product Type : Peptide

                          Upfront Cash : Not Applicable

                          April 21, 2022

                          Lead Product(s) : Colistimethate Sodium

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.

                          Product Name : AB21

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 21, 2022

                          Lead Product(s) : KABP022,KABP023,KABP033

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Ab-Biotics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Through the agreement, the company grants Zambon exclusive rights to commercialize Rivalif (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

                          Product Name : Rivalif

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 10, 2021

                          Lead Product(s) : Rivastigmine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Luye Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Data shows inhalation via the I-neb ® Adaptive Aerosol Delivery System of Promixin (colistimethate sodium) results in reduction of pulmonary exacerbations in non-cystic fibrosis bronchiectasis (NCFB) pat...

                          Product Name : Promixin

                          Product Type : Peptide

                          Upfront Cash : Not Applicable

                          September 08, 2021

                          Lead Product(s) : Colistimethate Sodium

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will ...

                          Product Name : Xadago

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 12, 2021

                          Lead Product(s) : Safinamide Mesylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Newron Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Not Applicable

                          April 28, 2020

                          Lead Product(s) : Cyclosporine

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank